Análisis de impacto presupuestal de everolimus más ciclosporina y prednisona comparado con micofenolato más ciclosporina y prednisona para la profilaxis del rechazo en los receptores de trasplante de riñón en Colombia

Orozco Ramirez, Luis Esteban; Sánchez Higuita, Edel Laura; Castro García, Paula Andrea; Contreras Ortiz, Javier Orlando.
Bogotá; IETS; mayo 2016. tab.
Monografia em Espanhol | BRISA, LILACS | ID: biblio-846814

Documentos relacionados

  1. Análisis de impacto presupuestal de everolimus más ciclosporina y prednisona comparado con micofenolato más ciclosporina y prednisona para la profilaxis del rechazo en los receptores de trasplante de corazón en Colombia
  2. Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients.
  3. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
  4. Interventions for focal segmental glomerulosclerosis in adults.
  5. Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients.
  6. Determinants of immunosuppressive therapy in renal transplant recipients: an Italian observational study (the CESIT project).
  7. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
  8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
  9. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
  10. Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters.